share_log

Brookline Capital Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

Brookline Capital Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

Brookline Capital將Incternal Therapeutics升級爲買入,宣佈目標股價爲2美元
Benzinga ·  2023/12/04 11:22

Brookline Capital analyst Kemp Dolliver upgrades Oncternal Therapeutics (NASDAQ:ONCT) from Hold to Buy and announces $2 price target.

布魯克林資本分析師坎普·多利弗將Oncternal Therapeutics(納斯達克股票代碼:ONCT)從持有上調至買入,並宣佈了2美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論